Moomiaie-Qajar said the decision to list in Hong Kong reflects the company's Asia-focused clinical relationships and its ambition to build a global biotech from the outset. "We have strategically selected a Hong Kong listing as our initial step, leveraging our established initiatives and partner relationships across Asia," he stated, adding that a U.S. secondary listing is designed to further diversify Axiom's investor base over time. The CEO added that Axiom is choosing public markets over private capital because it wants to move quickly from success in two rare pediatric indications toward larger adult opportunities. "Entering the public markets now positions us to strategically expand our clinical pipeline and fund the clinical entry of our deep preclinical portfolio," Moomiaie-Qajar commented. He believes that a successful Hong Kong debut could serve as "a case study for Hong Kong's ability to attract U.S. companies to list there," potentially opening the door for other American biotechs to rethink traditional financing routes.